RANCHO CORDOVA,
Calif., Sept. 13,
2018 /PRNewswire/ -- Cesca
Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell
processing and point-of-care, autologous cell-based therapies,
announced today that Chris Xu, PhD,
its chief executive officer, will be the keynote speaker on day two
of the Cell Therapy World Asia (CTWA) 2018 conference. The event
will be held at the Novotel Ambassador Seoul Gangnam Hotel, in
Seoul, South Korea, from
September 19 to 20, 2018.
Dr. Xu's address, entitled, "Impact of Automated Single-Use
Systems on Cost, Quality and Reproducibility of CAR-T Cell Therapy
Manufacturing," will begin at 9:00
a.m. KST on September
20th.
Cell Therapy World Asia is Asia-Pacific's only cell therapy-focused
regional event. It brings together Asia's best in cell therapy development and
manufacturing, and attracts cell therapy companies in South Korea, Japan, China,
India, Singapore, Taiwan, and the rest of Asia, to discuss and debate best practices and
innovation in the space. For more information, go to:
https://www.imapac.com/business_conference/cell-therapy-world-asia.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc.
(the "Company") develops, commercializes and markets a range of
automated technologies for CAR-T and other cell-based therapies.
Its device division, ThermoGenesis Corp., provides a full suite of
solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. The Company is
developing an automated, functionally-closed CAR-TXpress™ platform
to streamline the manufacturing process for the emerging CAR-T
immunotherapy market. For additional information, please go to:
http://www.cescatherapeutics.com.
Forward-Looking Statement
The statements contained
herein may include statements of future expectations and other
forward-looking statements that are based on management's current
views and assumptions and involve known and unknown risks and
uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. A more complete description of risks that could cause
actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics' annual report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cesca-therapeutics-chief-executive-officer-chris-xu-to-be-the-keynote-speaker-at-the-cell-therapy-world-asia-2018-conference-on-september-20-2018-300711880.html
SOURCE Cesca Therapeutics Inc.